Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma

Expert Opin Investig Drugs. 2011 Aug;20(8):1029-31. doi: 10.1517/13543784.2011.594793. Epub 2011 Jun 25.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials as Topic
  • Humans
  • Immunologic Factors / administration & dosage
  • Indoles / administration & dosage*
  • Lenalidomide
  • Lymphoma, B-Cell / drug therapy*
  • Molecular Targeted Therapy / methods
  • Rituximab
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Indoles
  • Rituximab
  • Thalidomide
  • Lenalidomide
  • enzastaurin